New hope for tough leukemia: experimental therapy CT0991 under study
NCT ID NCT06709131
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called CT0991 in people whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to check safety and find the right dose. About 24 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.